Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ORION CORPORATION PRESS RELEASE 23 JUNE 2026 at 9:30 EEST Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission Orion...
-
ORION OYJ LEHDISTÖTIEDOTE 23.6.2026 KLO 9.30 Orion Pharman ODM-212-molekyyli on saanut Euroopan komission myöntämän harvinaislääkestatuksen pahanlaatuisen mesoteliooman hoitoon ...
-
Annals of Internal Medicine publishes study showing potential benefits of Stockholm3 in identifying patients with aggressive prostate cancer.
-
OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series...
-
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution...
-
Steve Brown, founder and CEO of CureWise, will speak at Aspen Ideas: Health 2026, where he will launch the company’s AI-powered precision oncology platform
-
First patients dosed with BI 3820768 (OB33), marking third programme from the Oxford BioTherapeutics (OBT)-Boehringer Ingelheim collaboration to enter clinical development Obrixtamig reaches...
-
Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment optionsDAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as...
-
Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International Convention 2026
-
Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International Convention 2026